Skip Navigation LinksHome > October 2014 - Volume 35 - Issue 10 > Rifaximin suppresses background intestinal 18F-FDG uptake on...
Nuclear Medicine Communications:
doi: 10.1097/MNM.0000000000000170
Original Articles

Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans

Franquet, Elisaa,d; Palmer, Mathew R.a; Gifford, Anne E.b; Selen, Daryl J.a; Chen, Yih-Chieh S.a; Sedora-Roman, Nedaa; Joyce, Robin M.c; Kolodny, Gerald M.a,*; Moss, Alan C.b,*

Collapse Box


Background: Identification of cancer or inflammatory bowel disease in the intestinal tract by PET/computed tomography (CT) imaging can be hampered by physiological uptake of 18F-fluorodeoxyglucose (18F-FDG) in the normal colon. Previous work has localized this 18F-FDG uptake to the intestinal lumen, predominantly occupied by bacteria. We sought to determine whether pretreatment with an antibiotic could reduce 18F-FDG uptake in the healthy colon.

Patients and methods: Thirty patients undergoing restaging PET/CT for nongastrointestinal lymphoma were randomly selected to receive rifaximin 550 mg twice daily for 2 days before their scan (post-rifaximin). Their PET/CT images were compared with those from their prior study (pre-rifaximin). Cecal maximum standard uptake value (SUVmax) and overall colonic 18F-FDG uptake were compared between scans. All PET/CT images were blindly scored by a radiologist. The same comparison of sequential scans was also undertaken in 30 patients who did not receive antibiotics.

Results: Thirty post-rifaximin scans were compared with 30 pre-rifaximin scans in the same patients. SUVmax in the cecum was significantly lower in the patient’s post-rifaximin scans than in their pre-rifaximin scans (P=0.002). The percentage of scans with greater than grade 1 colonic 18F-FDG uptake was significantly lower in the post-rifaximin scans than in the pre-rifaximin scans (P<0.05). In contrast, there was no significant difference in the paired sequential scans from control patients, nor a reduction in the percentage of scans with greater than grade 1 colonic 18F-FDG uptake.

Conclusion: This pilot study shows that treatment with rifaximin for 2 days before PET/CT scanning can significantly reduce physiological 18F-FDG uptake in the normal colonic lumen.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Readers Of this Article Also Read